197 related articles for article (PubMed ID: 28629672)
21. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients.
Pfaar O; Sager A; Robinson DS
Pediatr Allergy Immunol; 2015 May; 26(3):280-286. PubMed ID: 25640879
[TBL] [Abstract][Full Text] [Related]
22. Safety of subcutaneous immunotherapy in patients with severe asthma.
Chow TG; Palka JM; Stone B; Trojan T; Epstein TG; Khan DA
Ann Allergy Asthma Immunol; 2022 Nov; 129(5):585-591.e3. PubMed ID: 35998846
[TBL] [Abstract][Full Text] [Related]
23. Adverse reactions to subcutaneous immunotherapy in patients with allergic rhinitis, a real-world study.
Zhang W; Deng Y; Tong H; Xiang R; Chen S; Kong Y; Tao Z; Xu Y
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4353-4360. PubMed ID: 33713192
[TBL] [Abstract][Full Text] [Related]
24. Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma.
Xiang L; Liu F; Zhi L; Jiang W; Liu C; Xie H; Zhou X; Sun Y; Zheng Y; Zhu R; Tao Z; Xia W; Lai H; Wei Q; Cheng L; Tang Y; Xu R; Huang H; Zhou Q; Chang P
Immunotherapy; 2021 Feb; 13(3):227-239. PubMed ID: 33317341
[No Abstract] [Full Text] [Related]
25. Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
Sánchez-Borges M; Bernstein DI; Calabria C
Immunol Allergy Clin North Am; 2020 Feb; 40(1):25-39. PubMed ID: 31761119
[TBL] [Abstract][Full Text] [Related]
26. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
[TBL] [Abstract][Full Text] [Related]
27. Are large local reactions a marker for systemic reactions to subcutaneous immunotherapy in children?
Simsek IE; Aydogan M
Asian Pac J Allergy Immunol; 2022 Mar; 40(1):75-80. PubMed ID: 34246207
[TBL] [Abstract][Full Text] [Related]
28. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma.
Har D; Lee MJ
Allergy Asthma Proc; 2019 Jan; 40(1):35-40. PubMed ID: 30582494
[No Abstract] [Full Text] [Related]
29. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors.
Epstein TG; Liss GM; Berendts KM; Bernstein DI
J Allergy Clin Immunol Pract; 2019; 7(6):1996-2003.e1. PubMed ID: 30776526
[TBL] [Abstract][Full Text] [Related]
30. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
[TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety.
Caminati M; Dama AR; Djuric I; Montagni M; Schiappoli M; Ridolo E; Senna G; Canonica GW
Expert Rev Clin Immunol; 2015 Feb; 11(2):233-45. PubMed ID: 25484197
[TBL] [Abstract][Full Text] [Related]
32. Diurnal variations in subcutaneous allergen immunotherapy reactions.
Bavishi AA; Grammer LC; Pongracic J; Rychlik K; Kumar R; Zee P; Greenberger PA; Fishbein AB
Ann Allergy Asthma Immunol; 2017 Jan; 118(1):103-107. PubMed ID: 27864091
[TBL] [Abstract][Full Text] [Related]
33. Systemic Reactions to Dust Mite Subcutaneous Immunotherapy: A 3-Year Follow-up Study.
Dong X; Huang N; Li W; Hu L; Wang X; Wang Y; Xiang N; Liu G; Zhu R
Allergy Asthma Immunol Res; 2016 Sep; 8(5):421-7. PubMed ID: 27334780
[TBL] [Abstract][Full Text] [Related]
34. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions?
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
Ann Allergy Asthma Immunol; 2013 Apr; 110(4):274-8, 278.e1. PubMed ID: 23535092
[TBL] [Abstract][Full Text] [Related]
35. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
Tabar AI; González Delgado P; Sánchez Hernández C; Basagaña Torrento M; Moreno Benítez F; Arina M
J Investig Allergol Clin Immunol; 2015; 25(1):40-6. PubMed ID: 25898693
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
Bahceciler NN; Cobanoglu N
Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
[TBL] [Abstract][Full Text] [Related]
37. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
[TBL] [Abstract][Full Text] [Related]
38. [Study on safty of standardized specific mite-allergen immunotherapy to children with allergic rhinitis and/or asthma].
Wu Y; Long Z; Huang Y; Huang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Jul; 25(14):641-4. PubMed ID: 22032122
[TBL] [Abstract][Full Text] [Related]
39. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
[TBL] [Abstract][Full Text] [Related]
40. Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults.
Guzmán-Fulgencio M; Caballero R; Lara B; Mena M; Tejera M; Sastre A; Subiza JL; Fernández-Caldas E; Casanovas M
Allergol Immunopathol (Madr); 2017; 45(2):198-207. PubMed ID: 27939406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
